Moderna Inc MRNA shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.
According to Moderna, the primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. Moderna says the trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.
See Also: Here's Why Affirm Raised Guidance Today
Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
